Metrics as of 10/13/2026, 06:35 PM (Berlin time), refresh in progress.
LENZ Therapeutics Stock
LENZ Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Evert Schimmelpennink
- Employees
- 152
- Market cap
- $107 M
- IPO
- 25/06/2021
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently…
LENZ Therapeutics stock: price history
1D
-5.8%
1W
-10.3%
1M
-24.8%
6M
-65.7%
YTD
-78.8%
1Y
-91.2%
2Y
-86.2%
5Y
-94.6%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~26% stronger price swings than usual
Ask the agents about LENZ Therapeutics
Analyst assessment of LENZ Therapeutics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 12/08/2026
LENZ Therapeutics stock metrics
P/E
-0.83
P/B
0.49
EV/EBITDA
-0.66
RETURN ON EQUITY
-14.6%
NET MARGIN
-581.8%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.3%
FLOAT SHARES
27,358,720
AVG. DAILY VOLUME (30D)
753,710
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about LENZ Therapeutics stock
What does LENZ Therapeutics do?
LENZ Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Evert Schimmelpennink, the company employs around 152 people.
The IPO was on 25/06/2021; the stock trades on NASDAQ under the ticker LENZ.
What do analysts say about LENZ Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does LENZ Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 26% stronger than usual.
Does LENZ Therapeutics pay a dividend?
Yes. The last dividend was US$1.03 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to LENZ Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get LENZ Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess LENZ Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.